Covid-19 roundup: J&J gives deep­est look yet at vac­cine; As­traZeneca shies away from dis­cussing vac­cine com­mer­cial op­por­tu­ni­ty

J&J has giv­en its deep­est look yet in­to its coro­n­avirus vac­cine can­di­date.

The NJ phar­ma and Op­er­a­tion Warp Speed mem­ber pub­lished the pre­clin­i­cal re­sults for their vac­cine in Na­ture Thurs­day morn­ing, show­ing that a sin­gle dose pro­vid­ed “com­plete or near-com­plete pro­tec­tion” from SARS-CoV-2 in rhe­sus macaques. The re­sults bol­stered a Phase I tri­al that is al­ready un­der­way, hav­ing launched in Bel­gium and the US.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.